These educational resources, tools, and materials are brought to you by our valued Corporate Members. For questions or more information, please email corporaterelations@oss-oncology.org for assistance.
Posted on 08.08.2024
The purpose of this Toolkit is to help support your experience as someone living with Diffuse Large B-Cell Lymphoma (DLBCL) or as a care partner by providing information to help you build a deeper understanding of DLBCL. This Toolkit was created by a group of patients, care partners, advocates and healthcare professionals brought together by Incyte, a pharmaceutical company working on behalf of the DLBCL community.
Posted on 07.30.2024
This resource is a guide for pharmacy directors and clinical pharmacists to help clinicians identify the subset of patients with clinical characteristics of advanced polycythemia vera (PV).
Posted on 07.30.2024
This resource is a step-by-step EMR guide for appropriate US population health decision makers or similar entities and their health systems to identify the subset of patients who may have clinical characteristics of advanced polycythemia vera (PV).
Posted on 07.18.2024
This resource is intended for patients looking to:
Posted on 07.18.2024
This resource is intended for eye doctors or oncologists looking to:
Published on: July 15, 2024
Gilead Oncology understands that metastatic breast cancer (MBC) is different from early breast cancer in many ways. Expose MBC is a platform for patients and their caregivers, friends, and family to share and gain honest information about their experiences, as well as to find resources, support, and community to help live their unique reality.
Visit and share this site with your patients.
Published on: July 2, 2024
Coherus is pleased to announce CMS has granted LOQTORZI® (toripalimab-tpzi) a product-specific J Code.
Published on: June 21, 2024
AMTAGVI (lifileucel) is a tumor-derived autologous T cell immunotherapy indicated for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor.
Published on: May 18, 2024
Learn about the importance of early detection and intervention for Breast Cancer-Related Lymphedema (BCRL). Hear expert insights into operationalizing a Lymphedema Surveillance Program, the role of bioimpedance spectroscopy (BIS) for early lymphedema detection, and updates on the latest clinical practice guidelines and research.
Published on: Apr 10, 2024
This new white paper demonstrates the time-burden on ER+, HER2- mBC patients and their loved ones when going to receive care and the potential difficulty of care when an IM injection is part of their treatment plan. It has been published by Ipsos and Living Beyond Breast Cancer, and is supported by Lilly.
Published on: Mar 24, 2024
This resource was created by Patient Resource and GO2 for Lung Cancer and produced with support from to provide patients and their loved ones with comprehensive information to guide them throughout their journey with small cell lung cancer. A Spanish-speaking version is available via download.
Free copies of this resource can be obtained by ordering it by:
💻 Visiting: https://okt.to/W7ib3U
✉️ Emailing: prp@patientresource.com
📞 Calling: 800-497-7530
Published on: Mar 24, 2024
Let's Chat CAR T website contains non-product specific educational materials for patients who have been diagnosed with certain blood cancers.
The website offers information that is helpful for patients and their caregivers who are considering CAR T-cell therapy (CAR T) as a treatment option or who are preparing to receive CAR T.
Topics include: